Company profile for Cyclerion Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion was founded with the goal of unlocking the full therapeutic potential of the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Imbalance in this pathway is linked to the pathophysiology...
We are a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion was founded with the goal of unlocking the full therapeutic potential of the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Imbalance in this pathway is linked to the pathophysiology of a wide range of cardiovascular, metabolic, inflammatory, fibrotic and neurological diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
301 Binney Street Cambridge, MA 02142
Telephone
Telephone
857-327-8778
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/09/23/3155076/0/en/Cyclerion-Announces-Transformational-Relaunch-as-a-Neuropsychiatric-Company.html

GLOBENEWSWIRE
23 Sep 2025

https://www.globenewswire.com/news-release/2024/12/17/2998240/0/en/Cyclerion-s-sGC-Stimulator-Portfolio-Generates-Revenues-to-Enable-Company-Growth.html

GLOBENEWSWIRE
17 Dec 2024

https://www.globenewswire.com/news-release/2024/08/07/2925801/0/en/Regina-Graul-Ph-D-Promoted-to-Chief-Executive-Officer.html

GLOBENEWSWIRE
07 Aug 2024

https://www.globenewswire.com//news-release/2023/12/04/2789962/0/en/Cyclerion-Appoints-Regina-Graul-Ph-D-as-President.html

GLOBENEWSWIRE
04 Dec 2023
Cyclerion Strengthens Board of Directors
Cyclerion Strengthens Board of Directors

30 Nov 2023

// GLOBENEWSWIRE

https://www.globenewswire.com//news-release/2023/11/30/2789032/0/en/Cyclerion-Strengthens-Board-of-Directors-with-Experienced-Company-Builder-and-Cutting-edge-Innovator.html

GLOBENEWSWIRE
30 Nov 2023

https://www.globenewswire.com/news-release/2023/07/31/2714726/0/en/Tisento-Launches-with-81-Million-From-Top-Tier-Investor-Syndicate-and-Promising-Cyclerion-Assets.html

GLOBENEWSWIRE
31 Jul 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty